1. Introduction
===============

Recently, the number of patients with critical limb ischemia (CLI) who undergo medical care at clinical practice sites has been increasing. Approaches to improve the outcome of treatment for these patients are important and urgent issues. The Japanese Society for Vascular Surgery (JSVS) has initiated a nationwide CLI registration and tracking database project since 2013 to obtain epidemiological data on CLI that can be shared among the medical staff. The background of CLI limbs, contents of treatment, early outcome, and long term outcome until 5 years after surgery, including non-surgical limbs, are registered in this database. The database was named JAPAN Critical Limb Ischemia Database (JCLIMB) and established on the National Clinical Database (NCD). The primary objective of the JCLIMB project is to clarify the current status of CLI treatment performed by vascular surgeons in Japan, and feed it back to physicians at practice sites to improve the quality of medical care. The initial registration data and their tracking data one month after registration in 2013 and in 2014 has already been published.^[@R1],[@R2])^ This article reports the basic data registered in 2015.

2. JCLIMB
=========

Details of the registration, including the definition of CLI, have already been described in the 2013 annual report.^[@R1])^ The followings are re-descriptions for confirmation.

CLI to be registered was defined according to TASC II^[@R3])^: chronic ischemic rest pain, ulcers or gangrene attributable to objectively proven arterial occlusive disease. The diagnosis of CLI should be confirmed by ankle pressure(AP) below 50 mmHg or by toe pressure (TP) below 30 mmHg in limbs with rest pain, and by AP below 70 mmHg or by TP below 50 mmHg in limbs with ulcer or gangrene.

The same limb can be registered in JCLIMB only once within a 5-year tracking period. When the registered limb is treated in different periods or at different institutions, such data should be added only to the tracking items of each limb in JCLIMB, avoiding overlapping registration as a new limb with CLI. However, details of the procedure are registered each time in NCD apart from the registration in JCLIMB. On the other hand, the patient with bilateral CLI can be registered twice for each limb. Fixing JCLIMB data is done as follows, based on NCD regulations:

Initial registration data: Early April in the following year

Tracking data early after treatment (1 month)/6 months after treatment: End of December in the following year

Tracking data 1 year after treatment: End of December after 2 years

Tracking data 2 years after treatment: End of December after 3 years

Tracking data 3 years after treatment: End of December after 4 years

Tracking data 4 years after treatment: End of December after 5 years

Tracking data 5 years after treatment: End of December after 6 years

As a general rule, the timing of tracking data registration is accepted within a ±2-month range until 12 months after treatment, and within a ±3-month range thereafter. Although the day for tracking data fixing is specified, it is made flexible because, in some limbs, follow-up data might be revealed later.

It was considered very difficult to make it obligatory for all the facilities participating in NCD to register CLI data since a great number of registration items in JCLIMB would put too much burden on them. Thus, facilities wishing to participate were recruited. In total, 92 facilities which registered CLI limbs in 2015 at the time of compiling in December 2016 are listed in the appendix.

Since JCLIMB is positioned as a registry study on NCD, the consent of patients for participation in the study and the ethical review of the study at the time of participation in NCD were adopted.

3. Comments on the Aggregated Data in 2015
==========================================

The initial registration data in 2015 were fixed early April 2016, and the tracking data early after treatment (one month) were fixed on December 31, 2016. At the time of December 2016, 1138 limbs, those of 796 males (70%) and 342 females (30%), were registered by 92 facilities. All data and extracted data on arteriosclerosis obliterans (ASO) were collected according to the registered items. Since ASO accounted for 98% of all limbs, the overall and ASO data showed a similar tendency. In the comments, ASO data were presented in parentheses only when its figure was different from that of the overall data. In addition, because the WIfI classification of the Society for Vascular Surgery (SVS) was reported in 2014 ([**Tables 1-1-1**](#table1-1-1){ref-type="table"} [to](#table1-1-2){ref-type="table"} [**1-1-3**](#table1-1-3){ref-type="table"}),^[@R4])^ JCLIMB has made several changes and additions to the registered items to make WIfI classification possible since 2015 ([**Tables 1-2-1**](#table1-2-1){ref-type="table"} [to](#table1-2-2){ref-type="table"} [**1-2-3**](#table1-2-3){ref-type="table"}). The total figure was not always consistent mostly due to missing values, and an explanation for each inconsistency was added.

###### Table 1-1 SVS WIfI classification: original 6) Table 1-1-1 Wound

  Grade                                                                                                                                          Ulcer                                                                                                            Gangrene
  ---------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  0                                                                                                                                              No ulcer                                                                                                         No gangrene
  Clinical description: ischemic rest pain (requires typical symptoms+ischemia grade 3); no wound.                                                                                                                                                                
  1                                                                                                                                              Small, shallow ulcer(s) on distal leg or foot; no exposed bone, unless limited to distal phalanx                 No gangrene
  Clinical description: minor tissue loss. Salvageable with simple digital amputation (1 or 2 digits) or skin coverage.                                                                                                                                           
  2                                                                                                                                              Deeper ulcer with exposed bone, joint or tendon; generally not involving the heel;                               Gangrenous changes limited to digits
  shallow heel ulcer, without calcaneal involvement                                                                                                                                                                                                               
  Clinical description: major tissue loss salvageable with multiple (≧3) digital amputations or standard TMA±skin coverage.                                                                                                                                       
  3                                                                                                                                              Extensive, deep ulcer involving forefoot and/or midfoot; deep, full thickness heel ulcer±calcaneal involvement   Extensive gangrene involving forefoot and/or midfoot; full thickness heel necrosis±calcaneal involvement
  Clinical description: extensive tissue loss salvageable only with a complex foot reconstruction or nontraditional TMA (Chopart or Lisfranc);                                                                                                                    
  ﬂap coverage or complex wound management needed for large soft tissue defect                                                                                                                                                                                    

TMA: Transmetatarsal amputation

###### Table 1-1-2 Ischemia

  Grade   ABI          AP (mmHg)   TP,TcPO~2~ (mmHg)
  ------- ------------ ----------- -------------------
  0       ≧0.80        \>100       ≧60
  1       0.60--0.79   70--100     40--59
  2       0.40--0.59   50--70      30--39
  3       ≦0.39        \<50        \<30

ABI: ankle brachial (pressure) index, AP: ankle pressure, PVR: pulse volume recording, SPP: skin perfusion pressure, TP: toe pressure, TcPO~2~: transcutaneous oximetry. Patients with diabetes should have TP measurements. If arterial calciﬁcation precludes reliable ABI or TP measurements, ischemia should be documented by TcPO~2~, SPP, PVR. If TP and ABI measurements result in different grades, TP will be the primary determinant of ischemia grade. Flat or minimally pulsatile forefoot PVR=grade 3.

###### Table 1-1-3 Foot Infection

  Grade                                                                                                                                                         Clinical manifestation of infection                                                                                                                                                                                                                         IDSA/PEDIS Infection severity\*
  ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  0                                                                                                                                                             No symptoms or signs of infection                                                                                                                                                                                                                           Uninfected
  1                                                                                                                                                             Infection present, as deﬁned by the presence of at least 2 of the following items:                                                                                                                                                                          Mild
  ·Local swelling or induration                                                                                                                                                                                                                                                                                                                                                                                             
  ·Erythema \>0.5 to ≦2 cm around the ulcer                                                                                                                                                                                                                                                                                                                                                                                 
  ·Local tenderness or pain                                                                                                                                                                                                                                                                                                                                                                                                 
  ·Local warmth                                                                                                                                                                                                                                                                                                                                                                                                             
  ·Purulent discharge (thick, opaque to white, or sanguineous secretion)                                                                                                                                                                                                                                                                                                                                                    
  Local infection involving only the skin and the subcutaneous tissue (without involvement of deeper tissues and without systemic signs as described below).                                                                                                                                                                                                                                                                
  Exclude other causes of an inﬂammatory response of the skin (e.g., trauma, gout, acute Charcot neuro-osteoarthropathy, fracture, thrombosis, venous stasis)                                                                                                                                                                                                                                                               
  2                                                                                                                                                             Local infection (as described above) with erythema \>2 cm, or involving structures deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis), and no systemic inﬂammatory response signs (as described below)   Moderate
  3                                                                                                                                                             Local infection (as described above) with the signs of SIRS, as manifested by two or more of the following:                                                                                                                                                 Severea^\#^
  ·Temperature \>38°C or \<36°C                                                                                                                                                                                                                                                                                                                                                                                             
  ·Heart rate \>90 beats/min                                                                                                                                                                                                                                                                                                                                                                                                
  ·Respiratory rate \>20 breaths/min or PaCO~2~ \<32 mmHg                                                                                                                                                                                                                                                                                                                                                                   
  ·White blood cell count \>12,000 or \<4,000 cu/mm or 10% immature (band) forms                                                                                                                                                                                                                                                                                                                                            

\*SVS adaptation of Infectious Diseases Society of America (IDSA) and International Working Group on the Diabetic Foot (IWGDF) perfusion, extent/size, PaCO~2~: partial pressure of arterial carbon dioxide, SIRS: systemic inﬂammatory response syndrome ^\#^ Ischemia may complicate and increase the severity of any infection. Systemic infection may sometimes manifest with other clinical ﬁndings, such as hypotension, confusion, vomiting, or evidence of metabolic disturbances, such as acidosis, severe hyperglycemia, new-onset azotemia.

###### Table 1-2 SVS WIfI classification: Correlation of WIfI and items in JCLIMB Table 1-2-1 Wound

  Grade     Rutherford classification                Ulcer                  Sites of gangrene                                   
  --------- ---------------------------------------- ---------------------- --------------------------------------------------- --------------------------------
  0         Class 4                                  No ulcer or gangrene                                                       
  1         Class 5, 6                               I                      Any portion                                         No gangrene
  II, III   Limited to digits                        No gangrene                                                                
  2         Class 5, 6                               I                      Heel                                                No gangrene
  II, III   Foot: distal metatarsal excluding heel   Limited to digits                                                          
  3         Class 5, 6                               II, III                Foot: proximal metatarsal, heel, ankle, lower leg   Extensive proximal to forefoot

###### Table 1-2-2 Ischemia

  Grade   SPP: (mmHg; calculating from the formula\*)
  ------- ---------------------------------------------
  0       ≧66
  1       37--65
  2       23--36
  3       \<23

\* TP=0.6853XSPP+14.48 SPP: skin perfusion pressure, TP: toe pressure

###### Table 1-2-3 Foot Infection

  Grade                                                                                                                                                                                                                    Local infection; foot   Systemic infection (SIRS)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------- ---------------------------
  0                                                                                                                                                                                                                        (−)                     (−)
  1                                                                                                                                                                                                                        (+)                     (−)
  Involving only the skin and the subcutaneous tissue (Erythema around the ulcer; 0.5--2 cm)                                                                                                                                                       
  2                                                                                                                                                                                                                        (+)                     (−)
  Involving only the skin and the subcutaneous tissue (Erythema around the ulcer; \>2 cm), or involving structures deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis)                           
  3                                                                                                                                                                                                                        (+)                     (+)

(1) Pretreatment patients' backgrounds
--------------------------------------

Pretreatment patients' backgrounds are shown in [**Tables 2-1**](#table2-1){ref-type="table"} to [**2-6**](#table2-6){ref-type="table"}. Control of blood pressure was judged as good when it was below 140/90 mmHg in the absence of diabetes and renal failure and below 130/80 mmHg in the presence of these diseases. Control of diabetes was judged as good when hemoglobin A1c (HbA1c) was below 7.0% (national glycohemoglobin standardization program \[NGSP\] value). Control of dyslipidemia was judged as good when low-density lipoprotein (LDL) was below 100 and 80 mg/dL in the absence and presence of other arteriosclerotic diseases, respectively. The presence of heart failure was judged clinically. The patient was regarded as having or having had heart failure when a past history of admission due to heart failure was present, clinical symptoms of heart failure were observed and confirmed on echocardiography, or cardiac function was clearly reduced on echocardiography although no clinical symptom was present. Renal dysfunction was graded following the new chronic kidney disease severity classification of the "Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2012"^[@R5])^: Renal dysfunction was absent when the estimated glomerular filtration rate (eGFR) (mL/min/1.73 m^2^) was 60 or higher, and it was graded as G3a, G3b, G4, and G5 when eGFR was 45--59, 30--44, 15--29, and below 15, respectively. eGFR below 15 in hemodialysis patients was graded as G5D.

The causes of the arterial occlusion of the limb were ASO in 1114 (98%) limbs, thromboangiitis obliterans (TAO) in 10, vasculitis (Takayasu's arteritis, collagen disease, Behçet's disease, and fibromuscular dysplasia excluding TAO) in eight, and others in six. Comorbidities of the patients consisted of diabetes in 67% (68%) of the limbs, hypertension in 73% (74%), dyslipidemia in 38% (39%), ischemic heart disease in 43% (44%), cerebrovascular disease in 22%, dialysis for renal failure in 43% (44%), past medical history of malignant neoplasm or that being treated in 8% (9%), and arterial occlusive lesions in the opposite limb in 75% (76%).

The problems and considerations on these spreadsheets are described below. In [**Table 2-4**](#table2-4){ref-type="table"}, describing the medical history of malignant neoplasm, the sum of the numbers in the column with the history of malignant neoplasm ("history of cancer", "under treatment", and "unknown") is larger than that of the numbers in the column with the sites of malignant neoplasm, in the row of limbs of Rutherford 5. As there might be duplicated cancers, the total number of sites of malignant neoplasm should be the same or more than that in the column with the history of malignant neoplasm. This is due to the following reasons. When "unknown" is selected about the information of malignancy, the input screen for the part of the malignancy is not displayed. As a result, the information on the site of malignancy was not input in five "unknown" limbs. In addition, because there were four limbs with duplicated cancer, the total number of sites of malignant neoplasm decreased by one as a whole.

###### Table 2 Patients' background  Table 2-1 Patients' background 1

  a\. Total                                                                                                                                                     
  -------------- -------- ------- ------------ -------------- --------------------- ------ ------------- ---- --- --- ------------- ------------- ------------- -------------
  Rutherford 4   241      166     75           118            123                   20.9   236           3    0   2   73.7 (10.5)   51.0 (22.1)   0.0--         55.5 (7.8)
  Rutherford 5   727      500     227          371            356                   20.9   710           6    7   4   73.5 (9.7)    46.0 (15.4)   64.0 (17.1)   78.5 (8.7)
  Rutherford 6   170      130     40           81             89                    21.1   168           1    1   0   71.2 (10.3)   59.0--        77.0--        0.0--
  Total          1,138    796     342          570            568                   20.9   1,114         10   8   6   73.2 (10.0)   48.8 (16.1)   65.6 (16.5)   70.8 (14.1)
  b\. ASO                                                                                                                                                       
                 n        Sex     Laterality   BMI (median)   Age at registration                                                                               
  Male           Female   Right   Left         Mean (±SD)                                                                                                       
  Rutherford 4   236      163     73           114            122                   20.9   73.7 (10.5)                                                          
  Rutherford 5   710      490     220          361            349                   20.9   73.5 (9.7)                                                           
  Rutherford 6   168      129     39           80             88                    21.1   71.2 (10.3)                                                          
  Total          1,114    782     332          555            559                   21.0   73.2 (10.0)                                                          

Vasculitis: Takayasu's arteritis, collagen disease, Behcet disease, FMD etc., excluding TAO. Others: others (including debranch bypasses for TEVAR or EVAR). ASO: arteriosclerosis obliterans, TAO: thromboangiitis obliterans, FMD: fibromuscular dysplasia, BMI: body mass index, TEVAR: thoracic endovascular aortic repair, EVAR: endovascular aneurysm repair

###### Table 2-2 Patients' background 2

  a\. Total                                                                                                                                      
  -------------- ------------ ------------------ -------------- ----------------- --------- ----- ----- ----- ----- ----- ----- ---- ----- ----- -----
  Rutherford 4   119          103                19             19                65        38    69    150   22    153   71    17   91    105   45
  Rutherford 5   225          403                99             58                231       213   179   479   69    446   238   43   300   309   118
  Rutherford 6   37           95                 38             16                48        69    64    90    16    105   54    11   67    76    27
  Total          381          601                156            93                344       320   312   719   107   704   363   71   458   490   190
  b\. ASO                                                                                                                                        
                 Diabetes     Diabetes therapy   Hypertension   Dyslipidemia      Smoking                                                        
  (−)            (+)          Diet therapy       Medication     Insulin therapy   (−)       (+)   (−)   (+)   (−)   (+)                          
  Management     Management   Management         Ex-smoker      Current smoker                                                                   
  Good           Poor         Good               Poor           Good              Poor                                                           
  Rutherford 4   117          100                19             19                64        36    65    149   22    149   70    17   90    103   43
  Rutherford 5   210          403                97             58                231       211   168   475   67    432   235   43   294   299   117
  Rutherford 6   35           95                 38             16                48        69    62    90    16    104   53    11   66    76    26
  Total          362          598                154            93                343       316   295   714   105   685   358   71   450   478   186

Blood pressure management good: diabetes or renal failure (−) \<140/90 mmHg, (+)\<130/80 mmHg. Diabetes management good: HbA1c\<7.0%(NGSP). Dyslipidemia management good: other sclerotic lesions (−) LDL\<100 mg/dL, (+) LDL\<80 mg/dL. HbA1c: hemoglobin A1c, LDL: low-density lipoprotein, NGSP: national glycohemoglobin standardization program

###### Table 2-3 Patients' background 3

  a\. Total                                                                                                                                                     
  ------------------- ------------------------ --------------- ------------------------- ------------------- ----- ----- ----- ----- ----- ----- ---- ---- ---- -----
  Rutherford 4        148                      33              35                        25                  213   28    194   47    107   33    24   12   0    65
  Rutherford 5        409                      90              122                       106                 637   90    564   163   218   65    54   32   5    353
  Rutherford 6        87                       29              33                        21                  141   29    130   40    59    14    7    10   5    75
  Total               644                      152             190                       152                 991   147   888   250   384   112   85   54   10   493
  b\. ASO                                                                                                                                                       
                      Ischemic heart disease   Heart failure   Cerebrovascular disease   Renal dysfunction                                                      
  (−)                 (+)                      (−)             (+)                       (−)                 (+)   (−)   (+)                                    
  Medical treatment   PCI                      CABG            G3a                       G3b                 G4    G5    G5D                                    
  Rutherford 4        143                      33              35                        25                  208   28    189   47    104   32    24   12   0    64
  Rutherford 5        395                      89              122                       104                 621   89    547   163   205   64    53   31   5    352
  Rutherford 6        85                       29              33                        21                  139   29    128   40    57    14    7    10   5    75
  Total               623                      151             190                       150                 968   146   864   250   366   110   84   53   10   491

PCI: percutaneous coronary intervention, CABG: coronary arterial bypass grafting Heart failure (+): history of admission due to heart failure, clinical symptoms due to heart failure confirmed by ultrasound examination, apparently decreased cardiac function by ultrasound examination without clinical symptoms. Renal dysfunction: (−) (60≦), G3a (45--59), G3b (30--44), G4 (15--29), G5 (\<15), G5D (\<15 with hemodialysis). New CKD risk stratification by eGFR(mL/min/1.73 m^2^) in "Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2012." eGFR: estimated glomerular filtration rate, CKD: chronic kidney disease

###### Table 2-4 Patients' background 4

  a\. Total                                                                                                                                                                                  
  ------------------- -------------------- ----------------------------- ----------- ------ --------- ------------------------ ------- ------ -------- --------- ---------- -------- --- --- ----
  Rutherford 4        212                  20                            9           0      2         0                        3       2      6        6         2          2        0   2   9
  Rutherford 5        668                  41                            13          5      5         0                        13      13     2        15        2          0        0   0   8
  Rutherford 6        157                  8                             4           1      1         1                        1       4      0        2         0          1        0   1   3
  Total               1,037                69                            26          6      8         1                        17      19     8        23        4          3        0   3   20
  b\. ASO                                                                                                                                                                                    
                      Malignant neoplasm   Sites of malignant neoplasm                                                                                                                       
  (−)                 (+)                  Head and neck                 Esophagus   Lung   Stomach   Hepatobiliary pancreas   Colon   East   Uterus   Ovarium   Prostate   Others           
  History of cancer   Under treatment\*    Unknown                                                                                                                                           
  Rutherford 4        207                  20                            9           0      2         0                        3       2      6        6         2          2        0   2   9
  Rutherford 5        651                  41                            13          5      5         0                        13      13     2        15        2          0        0   0   8
  Rutherford 6        155                  8                             4           1      1         1                        1       4      0        2         0          1        0   1   3
  Total               1,013                69                            26          6      8         1                        17      19     8        23        4          3        0   3   20

\* Including palliative therapy or recurrence.

###### Table 2-5 Patients' background 5

  a\. Total                                                                                                                                                                                                                                                             
  -------------- -------------------------------------- -------------------------------------- ---------------- -------- ----- -------- ----- -------- --------------------- ---------------------------- ------------------ -------- ------ ------- --- ---- ---- ---- ----
  Rutherford 4   67                                     50                                     42               36       13    0        33    175      0.82                  17                           0.64               72       38.5   217     0   12   2    7    3
  Rutherford 5   180                                    182                                    53               29       126   6        151   493      0.78                  58                           0.42               309      39.0   669     4   13   9    22   10
  Rutherford 6   34                                     44                                     9                5        13    24       41    93       0.75                  4                            0.32               68       42.5   159     0   3    1    6    1
  Total          281                                    276                                    104              70       152   30       225   761      0.78                  79                           0.44               449      40.0   1,045   4   28   12   35   14
  b\. ASO                                                                                                                                                                                                                                                               
                 Contralateral limb occlusive lesions   Vascular lesions excluding occlusion                                                                                                                                                                            
  (−)            (+)                                                                                                                                                                                                                                                    
  Asymptomatic   Intermittent claudication              CLI                                    Post-treatment   ABI      TBI   SPP      (−)   TAA      AAA (including IAA)   Peripheral artery aneurysm   Carotid stenosis   Others                                     
  R4             R5                                     R6                                     n                Median   n     Median   n     Median                                                                                                                    
  Rutherford 4   65                                     48                                     42               35       13    0        33    170      0.81                  16                           0.59               70       38.0   212     0   12   2    7    3
  Rutherford 5   170                                    181                                    52               29       123   6        149   480      0.78                  57                           0.41               305      39.0   657     3   11   7    22   10
  Rutherford 6   34                                     43                                     9                5        13    23       41    92       0.76                  4                            0.32               68       42.5   157     0   3    1    6    1
  Total          269                                    272                                    103              69       149   29       223   742      0.78                  77                           0.43               443      40.0   1,026   3   26   10   35   14

ABI: ankle brachial (pressure) index, TBI: toe brachial (pressure) index, SPP: skin perfusion pressure, CLI: critical limb ischemia, TAA: thracic aortic aneurysm, AAA: abdominal aortic aneurysm, IAA: iliac artery aneurysm

###### Table 2-6 Patients' background 6

  a\. Total (=ASO)                                              
  ------------------ ---- ------- ---- ------ ---- ------- ---- -----
  Rutherford 4       4    164.3   4    46.2   4    99.2    4    0.3
  Rutherford 5       22   139.8   22   64.6   22   110.6   22   0.4
  Rutherford 6       7    107.5   7    54.5   7    104.8   7    0.4
  Total              33   138.5   33   53.3   33   110.0   33   0.4

(2) Conditions of limb ischemia
-------------------------------

The pretreatment conditions of limb ischemia are shown in [**Tables 3-1**](#table3-1){ref-type="table"} [to](#table3-2){ref-type="table"}[](#table3-3){ref-type="table"}[](#table3-4){ref-type="table"}[](#table3-5){ref-type="table"} [**3-6**](#table3-6){ref-type="table"}. Regarding the walking function (Taylor classification),^[@R6])^ patients with the ability to walk outdoors or indoors independently, including with a cane, were regarded as "ambulatory", and those unable to walk but able to stand on their own legs during transfer from the bed to a wheel chair were designated as "ambulatory/homebound.﻿"

Regarding the state of local tissue defect (Texas University Classification),^[@R7])^ the most severe lesion being the main target of treatment was evaluated. Skin perfusion pressure (SPP) was measured on the foot (base of the toe, dorsum of the foot, or sole) and a lower value was adopted. In addition, in order to perform WIfI classification, the sites of ulcer and gangrene were registered separately. Although SPP is widely used as an objective index to evaluate ischemia in Japan, ischemic grading criteria using SPP is not shown in WIfI classification, in which TP is given top priority. Therefore, in JCLIMB, the SPP value was converted to TP using the conversion equation TP=0.6853 SPP+14.48 from the correlation data of SPP and TP reported in Japan,^[@R8])^ and applied for WIfI ischemic grading ([**Table 1-2-2**](#table1-2-2){ref-type="table"}).

The lesion was regarded as infected when it showed two or more of the following findings: local swelling or induration, erythema \>0.5 cm around the ulcer, local tenderness or pain, local warmth, purulent discharge (thick, opaque to white, or sanguineous secretion). In addition, local infections involving only the skin and the subcutaneous tissue and those involving structures deeper than the skin and subcutaneous tissues were registered separately. Local infections involving only the skin and the subcutaneous tissue were differentiated according to the size of the erythema around the ulcer, ≦2 or \>2 cm.

Systemic inflammatory response syndrome (SIRS), indicating systemic infection, was manifested by two or more of the following signs: temperature \>38°C or \<36°C, heart rate \>90 beats/min, respiratory rate \>20 breaths/min or PaCO~2~\<32 mmHg, white blood cell count \>12,000 or \<4000 cu/mm or 10% immature (band) forms. The arteries in the ankle joint region were classified as foot arteries.

Pretreatment ambulatory function was ambulatory in 55% of the limbs, ambulatory/homebound in 24%, and non-ambulatory in 21%. On Rutherford classification (R),^[@R9])^ limbs with categories R4, R5, and R6 accounted for 21%, 64%, and 15% of the limbs, respectively. The median ankle brachial index (ABI), the toe brachial index (TBI), and the SPP of the measured limbs was 0.61 (0.60), 0.27 (0.26), and 22 mmHg, respectively. The occlusive legion was located in the aortoiliac artery in 16% of the limbs, in the femoropopliteal artery in 41% (42%), and in the crural or foot artery in 43%.

We were able to apply the WIfI classification with sufficient data to 859 limbs (841 limbs). On the WIfI classification, limbs with the stages 1, 2, 3, and 4 accounted for 10%, 23%, 26% (27%), and 40% (41%) of the limbs, respectively.

The problems and considerations on these spreadsheets are described below. In [**Table 3-3**](#table3-3){ref-type="table"}, the total number of limbs in TASCII classification differed compared to the number in each column of the site of occlusion. In "aortoiliac" lesion, decreased number of that in TASCII classification may have been due to input omission. In "femoropopliteal" lesion, increased number of that in TASCII may have been due to inclusion of crural lesions.

In [**Table 3-6**](#table3-6){ref-type="table"}, there were 113 limbs (110 limbs) which classified to Wound grade 3 (W3; extensive ulcer/gangrene) in WIfI classification in the row of limbs of R5 (small-range tissue defect). Such results might have been obtained when there was a deep ulcer or gangrene in the heel, even if the wound was not extensive. In addition, any size of gangrene in parts other than toes, even if it was small, could be classified to W3.

In [**Table 3-6**](#table3-6){ref-type="table"}, 81 limbs (77 limbs) were registered as Ischemic grade 0 in WIfI classification. By definition, a limb with Ischemic grade 0 has a TP of 60 mmHg or more (SPP 66 mmHg or more in JCLIMB) or AP higher than 100 mmHg, or if arterial calcification precludes reliable AP or TP measurements, TcPO~2~ 60 mmHg, or more ([**Table 1-1-2**](#table1-1-2){ref-type="table"}). There should be no limb with Ischemic grade 0 since CLI to be registered in JCLIMB is defined according to TASC II. There is a possibility that the limbs clinically judged to be CLI were registered irrespective of the objective ischemic index, although details are unknown.

In [**Table 3-6**](#table3-6){ref-type="table"}, there were 24 limbs (23 limbs) in which infection was confirmed in R4 limbs, despite the absence of a local wound by definition of R4. The details are unclear whether the limb showed the symptoms of cellulitis without any wound or there was a small wound somewhere (in this situation it might be better to classify the limbs in R5).

In [**Table 3-6**](#table3-6){ref-type="table"}, because the data on ischemic grade were registered in only 859 limbs (841 limbs) among 1138 limbs (1114 limbs), WIfI classification could be implemented for these 859 limbs (841 limbs). When rechecking the remaining 279 limbs (273 limbs), the data on TBI, SPP, or ABI in these limbs were registered as unmeasurable or unmeasured. It seems to be unlikely that these ischemic indexes could not be measured in these limbs due to the extensive gangrene because 85 limbs with R4, 138 limbs (133 limbs) with R5 and 56 limbs (55 limbs) with R6 were included in this unmeasurable or unmeasured group. There is a possibility that the limbs clinically judged to be CLI were registered without their objective ischemic index.

###### Table 3 Pretreatment condition Table 3-1 Pretreatment condition 1

  a\. Total                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  --------------------------- --------------------------------------------- ---------------- ------------- ------------------------- -------------------------------------------- ------ ------- ----------- ------------------------- ---- ----- ----- -------- ------------------------- --------------------------- ------ ------- ----------- ------------------------- ----- ------------------------- --------------------------- ------ ------- ----------- ----
  Rutherford 4                172                                           48               21                                                                                                                                                                                                                                                                                                                                                                    
  Rutherford 5                403                                           178              146           560                       86                                           14     60      11          8                         59   446   137   144      358                       58                          11     35      2           3                         315   573                       82                          11     46      7           8
  Rutherford 6                52                                            52               66            66                        31                                           28     45      12          13                        29   32    35    103      71                        39                          32     35      5           11                        27    39                        34                          30     41      10          16
  Total                       627                                           278              233           626                       117                                          42     105     23          21                        88   478   172   247      429                       97                          43     70      7           14                        342   612                       116                         41     87      17          24
  b\. ASO                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                              Ambulatory function                           Sites of ulcer   Tissue loss   Sites of gangrene         Main sites of ulcer/gangrene to be treated                                                                                                                                                                                                                                                                                    
  (Taylor's classification)   (University of Texas classification: grade)                                                                                                                                                                                                                                                                                                                                                                                          
  Ambulatory                  Ambulatory/homebound                          Nonambulatory    Digits        Foot: distal metatarsal   Foot: proximal metatarsal                    Heel   Ankle   Lower leg   Only gangrene w/o ulcer   I    II    III   Digits   Foot: distal metatarsal   Foot: proximal metatarsal   Heel   Ankle   Lower leg   Only ulcer w/o gangrene   Toe   Foot: distal metatarsal   Foot: proximal metatarsal   Heel   Ankle   Lower leg   
  Rutherford 4                168                                           47               21                                                                                                                                                                                                                                                                                                                                                                    
  Rutherford 5                393                                           174              143           548                       83                                           13     59      11          8                         57   437   132   141      350                       56                          10     35      2           3                         308   561                       79                          10     45      7           8
  Rutherford 6                51                                            51               66            65                        30                                           28     44      12          13                        29   32    33    103      70                        38                          32     35      5           11                        27    39                        33                          30     40      10          16
  Total                       612                                           272              230           613                       113                                          41     103     23          21                        86   469   165   244      420                       94                          42     70      7           14                        335   600                       112                         40     85      17          24

University of Texas classification: grade (I: superficial, not involving tendon, capsule, or bone, II: penetrating to tendon/capsule, III: penetrating to bone or joint).

###### Table 3-2 Pretreatment condition 2

  a\. Total                                                                                                                                                                                                                                                                                       
  -------------- ------------------- ------------ -------------- -------------- -------- ------ -------- ----- -------------- -------------- ---------- ------ -------- ------ -------- ------------ ------------------------------------------ ----------------- ---------- ----- ---- ---- ---- -------
  Rutherford 4   232                 9            230            6,725          214      0.55   215      3.6   229            1.08           121        0.56   8        0.41   86       20           8                                          51.5              217        12    5    7    5    237
  Rutherford 5   688                 39           710            7,300          690      1.00   669      3.4   712            2.28           463        0.61   31       0.26   432      22           31                                         36                480        168   50   33   19   709
  Rutherford 6   143                 27           169            8,600          169      4.62   161      2.9   169            1.90           79         0.66   3        0.18   92       22.5         3                                          27                50         31    36   54   16   154
  Total          1,063               75           1,109          7,400          1,073    1.16   1,045    3.4   1,110          1.54           663        0.61   42       0.27   610      22           42                                         36                747        211   91   94   40   1,100
  b\. ASO                                                                                                                                                                                                                                                                                         
                 Temperature ≧38°C   Blood test   Hemodynamics   Infection^&^                                                                                                                                                                                                                     
  (−)            (+)                 WBC          CRP            Alb            Cr       ABI    TBI      SPP   Toe pressure   Local (foot)   Systemic                                                                                                                                             
  n              Median              n            Median         n              Median   n      Median   n     Median         n              Median     n      Median   n      Median   Uninfected   Skin or subcutaneous tissue (erythema)\*   Deep tissue^\#^   SIRS^\$^                        
  ≦2.0 cm        \>2.0 cm            (+)          (−)                                                                                                                                                                                                                                             
  Rutherford 4   227                 9            225            6,700          209      0.54   210      3.6   224            1.09           119        0.55   8        0.41   83       20           8                                          51.5              213        11    5    7    5    232
  Rutherford 5   673                 37           694            7,300          675      1.00   654      3.4   696            2.78           452        0.61   30       0.25   427      22           30                                         36                467        166   50   30   17   694
  Rutherford 6   142                 26           167            8,550          167      4.62   159      2.9   167            1.94           78         0.66   3        0.18   91       22           3                                          27                50         31    34   54   16   152
  Total          1,042               72           1,086          7,375          1,051    1.17   1,023    3.4   1,087          1.61           649        0.60   41       0.26   601      22           41                                         36                730        208   89   91   38   1,078

WBC: white blood cell, CRP: C reactive protein, Alb: albumin, Cr: creatinine, ABI: ankle brachial (pressure) index, TBI: toe brachial (pressure) index, SPP: skin perfusion pressure, SIRS: systemic inflammatory response syndrome ^&^ Presence of infection is defined by the presence of at least 2 of the following items: ①Local swelling or induration, ②Erythema \>0.5 to ≦2 cm around the ulcer, ③Local tenderness or pain, ④Local warmth, ⑤Purulent discharge (thick, opaque to white, or sanguineous secretion). \* Local infection at skin and subcutaneous tissue was classified by the spreading of erythema (≦2.0 cm or \>2 cm) around the ulcer/gangrene. ^\#^ Local infection involving structures deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis). ^\$^ The signs of SIRS are manifested by two or more of the following: ①Temperature \>38 or \<36°C, ②Heart rate \>90 beats/min, ③Respiratory rate \>20 breaths/min or PaCO~2~ \<32 mmHg, ④White blood cell count \>12,000 or \<4,000 cu/mm or 10% immature (band) forms.

###### Table 3-3 Pretreatment condition 3

  a\. Total                                                                                                                                                                                                                 
  -------------- -------------------- -------------------- ----------------------------------- ---------------------------------------- ---------------- ----- ---- ---- ---- ----------- --- ----- ----- ----- ----------- -----
  Rutherford 4   165                  121                  18                                  79                                       161              105   20   8    6    36          3   19    35    24    106         13
  Rutherford 5   531                  328                  28                                  137                                      435              489   44   28   15   49          0   112   103   94    244         107
  Rutherford 6   136                  51                   11                                  41                                       81               113   11   13   5    9           1   15    10    13    67          37
  Total          832                  500                  57                                  257                                      677              707   75   49   26   94          4   146   148   131   417         157
  b\. ASO                                                                                                                                                                                                                   
                 Diagnostic imaging   Sites of occlusion   TASC II classification aortoiliac   TASC II classification femoropopliteal                                                                                       
  IADSA          CTA                  Others               Aortoiliac                          Femoropop                                Lower leg/foot   A     B    C    D    No lesion   A   B     C     D     No lesion   
  Rutherford 4   162                  118                  18                                  79                                       158              100   20   8    6    36          3   19    35    24    101         13
  Rutherford 5   517                  323                  26                                  134                                      429              475   44   27   15   47          0   112   103   92    237         101
  Rutherford 6   134                  50                   11                                  41                                       80               111   11   13   5    9           1   15    10    13    65          37
  Total          813                  491                  55                                  254                                      667              686   75   48   26   92          4   146   148   129   403         151

IADSA: intra-arterial digital subtraction angiography, CTA: computed tomography angiography

###### Table 3-4 Pretreatment condition 4

  a\. Total                                                                                                                                                                                                           
  ---------------- ----------------- ------------------------------- ----------------------------- --------------------- ------------------- --------------------- -------- ------ -------- --- -------- --- -------- ---
  Rutherford 4     115               3                               115                           2                     115                 5                     115      12     114      5   114      3   112      3
  Rutherford 5     461               1                               457                           1                     463                 3                     461      4      464      3   466      2   463      3
  Rutherford 6     105               1                               103                           1                     106                 3                     105      4      105      2   106      2   106      3
  Total            681               1                               675                           1                     684                 3                     681      4      683      3   686      2   681      3
  b\. ASO                                                                                                                                                                                                             
                   Bollinger score                                                                                                                                                                                    
  Common femoral   Deep femoral      Superficial femoral: proximal   Superficial femoral: distal   Popliteal: proximal   Popliteal: distal   Tibioperoneal trunk                                                      
  n                Median            n                               Median                        n                     Median              n                     Median   n      Median   n   Median   n   Median   
  Rutherford 4     112               3                               112                           2                     112                 5                     112      10.5   111      5   111      3   109      3
  Rutherford 5     451               1                               447                           1                     453                 3                     451      4      454      3   456      2   454      3
  Rutherford 6     104               1                               102                           1                     105                 3                     104      4      104      2   105      2   105      3
  Total            667               1                               661                           1                     670                 3                     667      4      669      3   672      2   668      3

###### Table 3-5 Pretreatment condition 5

  a\. Total                                                                                                                                                                                                       
  ---------------------------- -------------------------- --------------------------- ------------------------- -------------------- ------------------ ------ -------- ------ -------- --- -------- --- -------- ----
  Rutherford 4                 112                        13                          108                       6                    112                13     106      12.5   111      6   105      5   93       6
  Rutherford 5                 462                        15                          456                       13                   461                13     456      13     458      6   454      6   409      13
  Rutherford 6                 106                        13                          104                       13                   105                13     103      13     105      6   104      6   97       13
  Total                        680                        13.5                        668                       13                   678                13     665      13     674      6   663      6   599      13
  b\. ASO                                                                                                                                                                                                         
                               Bollinger score                                                                                                                                                                    
  Posterior tibial: proximal   Posterior tibial: distal   Anterior tibial: proximal   Anterior tibial: distal   Peroneal: proximal   Peroneal: distal   Foot                                                      
  n                            Median                     n                           Median                    n                    Median             n      Median   n      Median   n   Median   n   Median   
  Rutherford 4                 109                        13                          106                       6                    109                12     103      12     108      6   103      5   91       5
  Rutherford 5                 452                        15                          446                       13                   451                13     446      13     448      6   444      6   401      13
  Rutherford 6                 105                        13                          103                       13                   104                13     102      13     104      6   103      6   96       13
  Total                        666                        13                          655                       13                   664                13     651      13     660      6   650      6   588      13

###### Table 3-6 SVS WIfI classification

  a\. Total                                                                                                                 
  -------------- ------- ---------- ---------------- ------- ---- ----- ----- ----- ----- ----- ----- ---- ---- ----- ----- -----
  Rutherford 4   241     0          0                0       16   31    46    63    217   10    11    3    44   103   7     2
  Rutherford 5   0       263        351              113     52   107   173   257   478   161   71    17   42   93    204   250
  Rutherford 6   0       10         43               117     13   19    30    52    50    30    74    16   2    3     14    95
  Total          241     273        394              230     81   157   249   372   745   201   156   36   88   199   225   347
  b\. ASO                                                                                                                   
                 Wound   Ischemia   Foot infection   Stage                                                                  
  0              1       2          3                0       1    2     3     0     1     2     3     1    2    3     4     
  Rutherford 4   236     0          0                0       16   31    44    60    213   9     11    3    44   99    6     2
  Rutherford 5   0       257        343              110     48   106   170   253   465   160   70    15   40   89    203   245
  Rutherford 6   0       10         43               115     13   19    29    52    50    30    72    16   2    3     14    94
  Total          236     267        386              225     77   156   243   365   728   199   153   34   86   191   223   341

(3) Treatment
-------------

[**Tables 4-1**](#table4-1){ref-type="table"} [to](#table4-2){ref-type="table"}[](#table4-3){ref-type="table"}[](#table4-4){ref-type="table"}[](#table4-5){ref-type="table"} [**4-6**](#table4-6){ref-type="table"} show the data on the treatment of CLI. Revascularizations of the affected limbs were performed in 96% of the registered limbs, and primary major amputations were performed in 1.9% of the registered limbs. Among the procedures of surgical reconstruction, distal bypass, which is a bypass to the crural or foot artery, accounted for 46% (45%). Endovascular treatment (EVT), including EVT alone and hybrid treatment with surgical reconstruction, accounted for 58% (59%) of the total revascularization procedures. EVT applied to the crural or foot artery accounted for 39% of the total EVT.

The problems and considerations on these spreadsheets are described below. [**Table 4-3**](#table4-3){ref-type="table"}, in the column of "vein usage" described how the autologous veins were used when they were selected as vascular conduits. The sum of the number in the column with vein usage; "in-situ," "non-reversed," "reversed" and "spliced," is larger than the sum of the number in the column of vein in vascular prosthesis. It is speculated to be caused by selecting multiple vein usage for arterial reconstruction of a limb since it is permitted to select more than one vein usage.

[**Table 4-6**](#table4-6){ref-type="table"} summarizes the vascular grafts used for the infra-inguinal arterial reconstruction. For example, the total number of femoral-above knee popliteal artery bypass was 109 (107), higher than 102 (100), the number of actual applications in [**Table 4-2**](#table4-2){ref-type="table"}. It may have reflected the content of other procedures because the bypass procedure can be simultaneously applied with other procedures. Multiple procedures can be selected at the same time for lower limb arterial reconstruction. This is also the reason for the presence of "unused.﻿﻿﻿"

###### Table 4 Treatment Table 4-1 Treatment 1

  a\. Total                                                                                                                                                                                     
  ------------------------- -------------------- ------------------------- ------------------ ---------------------- ------------- ------------------ -------- --------- ----- ----- ----- ---- ----
  Rutherford 4              61                   1                         228                2                      0             0                  0        0         0     177   44    9    11
  Rutherford 5              185                  3                         704                5                      0             0                  0        1         2     555   114   24   32
  Rutherford 6              39                   2                         158                14                     0             0                  0        0         0     127   21    9    13
  Total                     285                  6                         1,090              21                     0             0                  0        1         2     859   179   42   56
  b\. ASO                                                                                                                                                                                       
                            Treatment            Angiogenic therapy        Reoperation                                                                                                          
  Pharmacological therapy   Angiogenic therapy   Arterial reconstruction   Major amputation   Lumber sympathectomy   Bone marrow   Peripheral blood   Others   Unknown   (−)   (+)              
  1X                        2X                   3X≦                                                                                                                                            
  Rutherford 4              61                   1                         223                2                      0             0                  0        0         0     173   44    9    10
  Rutherford 5              181                  3                         687                5                      0             0                  0        1         2     541   112   23   32
  Rutherford 6              39                   2                         156                14                     0             0                  0        0         0     125   21    9    13
  Total                     281                  6                         1,066              21                     0             0                  0        1         2     839   177   41   55

###### Table 4-2 Treatment 2

  a\. Total                                                                                                                                                                                                                                                                                              
  -------------- ------------------------------- --------------- ---------------------------- -------------------------- --------------------- ----------------------- ------------------- ------------------ ----------------- ------------------------- ------------- ------------------- -------- --- -----
  Rutherford 4   0                               0               6                            27                         18                    37                      12                  0                  10                9                         2             1                   22       1   111
  Rutherford 5   0                               0               13                           62                         41                    93                      103                 3                  16                21                        1             2                   47       5   365
  Rutherford 6   0                               0               1                            13                         9                     24                      30                  0                  3                 2                         1             0                   15       1   74
  Total          0                               0               20                           102                        68                    154                     145                 3                  29                32                        4             3                   84       7   550
  b\. ASO                                                                                                                                                                                                                                                                                                
                 Bypass                          TEA             EVT                                                                                                                                                                                                                                     
  Aorta-aorta    Aorta (with suprarenal clamp)   Aorta-femoral   Femoral-proximal popliteal   Femoral-distal popliteal   Femoral-crural/foot   Popliteal-crural/foot   Anatomical others   Axillary-femoral   Femoral-femoral   Extra-anatomical others   Aorta/iliac   Fomoral/popliteal   Others       
  Rutherford 4   0                               0               6                            27                         17                    34                      11                  0                  10                9                         2             1                   22       1   110
  Rutherford 5   0                               0               13                           61                         39                    90                      98                  2                  16                20                        1             2                   47       5   360
  Rutherford 6   0                               0               1                            12                         9                     23                      30                  0                  3                 2                         1             0                   15       1   74
  Total          0                               0               20                           100                        65                    147                     139                 2                  29                31                        4             3                   84       7   544

TEA: thromboendarterectomy, EVT: endovascular treatment

###### Table 4-3 Treatment 3

  a\. Total                                                                                                                                                                      
  -------------- ------------------- --------------------- ------------ -------------- ------- ------ -------- ----- --------- -------------- ---------- --------- ------ ------ ----
  Rutherford 4   39                  53                    37           5              8       36     71       6     13        13             22         31        7      64     7
  Rutherford 5   85                  176                   197          5              32      81     246      2     24        53             68         104       26     211    35
  Rutherford 6   24                  26                    35           2              4       10     66       1     12        13             29         24        3      61     5
  Total          148                 255                   269          12             44      127    383      9     49        79             119        159       36     336    47
  b\. ASO                                                                                                                                                                        
                 EVT                 Vascular prosthesis   Vein usage   Vein quality                                                                                             
  Aorta/iliac    Femoral/popliteal   Tibioperoneal/foot    Others       Polyester      ePTFE   Vein   Others   (−)   In-situ   Non-reversed   Reversed   Spliced   Good   Poor   
  Rutherford 4   39                  53                    36           5              8       36     67       6     13        11             22         29        7      60     7
  Rutherford 5   84                  176                   193          5              32      78     238      2     23        52             64         100       26     204    34
  Rutherford 6   24                  26                    35           2              4       10     64       1     12        13             28         23        3      59     5
  Total          147                 255                   264          12             44      124    369      9     48        76             114        152       36     323    46

ePTFE: expanded polytetrafluoroethylene, EVT: endovascular treatment

###### Table 4-4 Treatment 4

  a\. Total                                                                                                                                                                                                                                                                                                                                                      
  ---------------------- -------------------- -------------------------------------------- ------------------------------------------ -------------------- ------------------ -------- -------- -------- ------ --------------------- ------------------ ----------------- ---------- ------------------ ----------------- ---------- ---------------- --------- ----
  Rutherford 4           1                    21                                           2                                          11                   8                  4        1        1        26     23                    3                  14                3          6                  10                3          0                8         2
  Rutherford 5           2                    41                                           7                                          45                   21                 69       8        3        63     133                   3                  27                28         5                  39                11         0                66        17
  Rutherford 6           0                    10                                           1                                          9                    4                  24       6        0        21     33                    3                  6                 9          3                  12                3          0                16        2
  Total                  3                    72                                           10                                         65                   33                 97       15       4        110    189                   9                  47                40         14                 61                17         0                90        21
  b\. ASO                                                                                                                                                                                                                                                                                                                                                        
                         Distal bypass                                                                                                                                                                                                                                                                                                                           
  Proximal anastomosis   Distal anastomosis   Distal anastomosis: sites of crural artery   Distal anastomosis: sites of foot artery                                                                                                                                                                                                                              
  External iliac         Common femoral       Deep femoral                                 Superficial femoral                        Proximal popliteal   Distal popliteal   Crural   Others   Crural   Foot   Tibioperoneal trunk   Posterior tibial   Anterior tibial   Peroneal   Posterior tibial   Anterior tibial   Peroneal   Dorsalis pedis   Plantar   
  Rutherford 4           1                    18                                           2                                          11                   8                  3        1        1        24     21                    3                  13                2          6                  8                 3          0                8         2
  Rutherford 5           2                    41                                           6                                          41                   20                 67       8        3        58     130                   3                  27                24         4                  39                11         0                65        15
  Rutherford 6           0                    10                                           1                                          8                    4                  24       6        0        20     33                    3                  6                 8          3                  12                3          0                16        2
  Total                  3                    69                                           9                                          60                   32                 94       15       4        102    184                   9                  46                34         13                 59                17         0                89        19

###### Table 4-5 Treatment 5

  a\. Total                                                                            
  -------------- ------------------------- --------------- --------- -------- -------- ----
  Rutherford 4   107                       8               2         3        13       6
  Rutherford 5   341                       35              38        20       31       16
  Rutherford 6   70                        8               5         3        8        5
  Total          518                       51              45        26       52       27
  b\. ASO                                                                              
                 Pharmacological therapy                                               
  Antiplatelet   ATA                       Prostaglandin   Heparin   Statin   Others   
  Rutherford 4   107                       8               2         3        13       6
  Rutherford 5   335                       34              36        19       30       13
  Rutherford 6   70                        8               5         3        8        5
  Total          512                       50              43        25       51       24

Antiplatelet: aspirin, cilostazol, beraprost, sarpogrelate, ticlopidine, clopidogrel, ethyl icosapentate. ATA: antithrombotic agent

###### Table 4-6 Treatment 6

  a\. Total                                                                                                      
  ----------- ----------------------------------- --------------------------------- ---------------------------- ------------------------------
  Polyester   9                                   5                                 1                            2
  ePTFE       57                                  14                                9                            7
  Vein        39                                  52                                139                          135
  Artery      1                                   0                                 7                            5
  Others      2                                   0                                 1                            1
  (−)         1                                   0                                 0                            1
  Total       109                                 71                                157                          151
  b\. ASO                                                                                                        
              Femoral-proximal popliteal bypass   Femoral-distal popliteal bypass   Femoral-crural/foot bypass   Popliteal-crural/foot bypass
  Polyester   9                                   5                                 1                            2
  ePTFE       57                                  13                                8                            7
  Vein        37                                  50                                134                          129
  Artery      1                                   0                                 6                            5
  Others      2                                   0                                 1                            1
  (−)         1                                   0                                 0                            1
  Total       107                                 68                                150                          145

ePTFE: expanded polytetrafluoroethylene

(4) Outcomes early (one month) after treatment
----------------------------------------------

[**Tables 5-1**](#table5-1){ref-type="table"}[](#table5-2){ref-type="table"}[](#table5-3){ref-type="table"}[](#table5-4){ref-type="table"}[](#table5-5){ref-type="table"}[](#table5-6){ref-type="table"}[](#table5-7){ref-type="table"} to [**5-8**](#table5-8){ref-type="table"} show the outcomes early (one month) after treatment. At the time of summary count at the end of December 2016, follow-up data one month after treatment were obtained in 837 limbs (74%) including 816 limbs (73%) with ASO. There were 36 limbs with non-arterial reconstruction. Data were collected according to the severity of the local conditions of the limb (Rutherford classification) and treatment measures (EVT alone or surgical reconstruction with/without EVT). The mortality was 2.6% (2.7%) in the whole series, and 2.3% and 3.1% (3.2%) treated by EVT alone and by surgical reconstruction with/without EVT, respectively. The most common cause of death was cardiac disease, accounting for 27% of all deaths.

Postoperative complications were cardiac disease in 2.1% (2.2%), cerebrovascular disease in 0.8%, pneumonia in 1.6% (1.7%), and wound complication in 5.0% (4.8%). Complications at the puncture site were noted in 0.5% of limbs treated by EVT. The median ABI and SPP of the measured limbs were 0.89 and 43 mmHg, respectively.

Stenosis, occlusion, and infection occurred after revascularization by EVT in 9.9% (9.7%) and by surgical reconstruction in 8.3% (7.6%). Secondary major amputation was performed in 4.6% (4.3%) of the limbs.

When ambulatory function at discharge was compared with that before surgery, the rate of patients with ambulatory changed from 55% to 53% (52%), ambulatory/homebound from 24% to 23%, and nonambulatory from 21% to 24% (25%).

The problems, comments, and considerations on these spreadsheets are described below. Among 36 limbs of survivors with non-arterial reconstruction ([**Table 5-1**](#table5-1){ref-type="table"}), 4 limbs underwent primary major amputation and were counted in the column of perioperative complications in the row of limbs with non-arterial reconstruction ([**Table 5-2**](#table5-2){ref-type="table"}). Therefore, 36 limbs of survivors with non-arterial reconstruction comprised 4 limbs with primary major amputation and 32 limbs with conservative treatment.

The number of limbs of survivors with EVT was 344 (339 limbs) ([**Table 5-1**](#table5-1){ref-type="table"}), which was 5 limbs higher than the sum of the number in the column of minor reintervention or major reintervention in the row of limbs with EVT; 339 limbs (334 limbs) ([**Table 5-6**](#table5-6){ref-type="table"}). Four of these 5 limbs underwent major amputation after EVT, and reintervention was not performed. The information related to reintervention on the remaining one limb was missing.

The number of limbs of survivors with surgical reconstruction was 435 (419 limbs) ([**Table 5-1**](#table5-1){ref-type="table"}), which was one limb higher than the sum of the number in the column of minor reintervention or major reintervention in the row of limbs with surgical reconstruction; 434 limbs (418 limbs) ([**Table 5-6**](#table5-6){ref-type="table"}). This one limb also underwent major amputation after surgical reconstruction, and reintervention was not performed.

In [**Table 5-6**](#table5-6){ref-type="table"}, the sum of the number of limbs in the column of "major amputation" was expected to be 811 limbs (790 limbs); the limbs of survivors without major amputation comprised 32 limbs with conservative treatment, 344 limbs (339 limbs) with EVT, and 435 limbs (419 limbs) with surgical reconstruction. But the actual sum of the number of limbs in the column of major amputation was 808 (787), indicating 3 limbs fewer than expected. This was due to unregistered limbs with EVT; the sum of the number of limbs in the row of EVT was 341 (336), indicating that 3 limbs were unregistered.

In addition to the above, there were some parts where the total number does not match in [**Tables 5-1**](#table5-1){ref-type="table"} [to](#table5-2){ref-type="table"}[](#table5-3){ref-type="table"}[](#table5-4){ref-type="table"}[](#table5-5){ref-type="table"}[](#table5-6){ref-type="table"}[](#table5-7){ref-type="table"} [**5-8**](#table5-8){ref-type="table"}. It is estimated to be due to several items with multiple choice or missing values.

###### Table 5 Outcomes early (one month) after treatment therapeutic measures: EVT (only EVT without surgical reconstruction), Surgical reconstruction (surgical reconstruction with or without EVT) Table 5-1 Life prognosis/causes of death

  a\. Total                                                                                                                                                                                                                                                      
  ------------------------- -------------------- ----------------- ----------------- ------------------------- -------------------- ---------------------------- ----------- -------------------- --------------------------- -------- --------- --- --- --- --- ---
  Local condition           Rutherford 4         162               5                 0                         1                    0                            0           0                    0                           0        0         0   0   0   3   1
  Rutherford 5              538                  14                0                 4                         0                    0                            0           1                    0                           2        1         2   0   3   1   
  Rutherford 6              115                  3                 0                 1                         0                    0                            0           0                    0                           0        1         0   0   0   1   
  Therapeutic measures      Non-reconstruction   36                0                 0                         0                    0                            0           0                    0                           0        0         0   0   0   0   0
  EVT                       344                  8                 0                 3                         0                    0                            0           1                    0                           1        0         0   0   3   0   
  Surgical reconstruction   435                  14                0                 3                         0                    0                            0           0                    0                           1        2         2   0   3   3   
  Total                     815                  22                0                 6                         0                    0                            0           1                    0                           2        2         2   0   6   3   
  b\. ASO                                                                                                                                                                                                                                                        
                            Life prognosis       Causes of death                                                                                                                                                                                                 
  Alive                     Dead                 Unknown           Cardiac disease   Cerebrovascular disease   Malignant neoplasm   Aortic aneurysm/dissection   Infection   Ischemic enteritis   Gastrointestinal bleeding   Others   Unknown                   
  Hemorrhage                Infarction           Unknown           Diseased limb     Others                                                                                                                                                                      
  Local condition           Rutherford 4         157               5                 0                         1                    0                            0           0                    0                           0        0         0   0   0   3   1
  Rutherford 5              523                  14                0                 4                         0                    0                            0           1                    0                           2        1         2   0   3   1   
  Rutherford 6              114                  3                 0                 1                         0                    0                            0           0                    0                           0        1         0   0   0   1   
  Therapeutic measures      Non-reconstruction   36                0                 0                         0                    0                            0           0                    0                           0        0         0   0   0   0   0
  EVT                       339                  8                 0                 3                         0                    0                            0           1                    0                           1        0         0   0   3   0   
  Surgical reconstruction   419                  14                0                 3                         0                    0                            0           0                    0                           1        2         2   0   3   3   
  Total                     794                  22                0                 6                         0                    0                            0           1                    0                           2        2         2   0   6   3   

EVT: endovascular treatment

###### Table 5-2 Perioperative complications 1

  a\. Total                                                                                                                                                                                                                 
  ------------------------- --------------------- ---------------------------- ----------------------- -------------------- --------------------- --------------------- ----- ----- ----- ----- ----- ----- ----- ----- --- ---
  Local condition           Rutherford 4          153                          0                       0                    3                     156                   0     0     0     154   2     149   7     155   0   1
  Rutherford 5              512                   4                            4                       4                    518                   2                     1     3     516   8     492   32    519   3     2   
  Rutherford 6              111                   1                            0                       1                    113                   0                     0     0     110   3     112   1     113   0     0   
  Therapeutic measures      Non-reconstruction    4                            0                       0                    0                     4                     0     0     0     4     0     4     0     4     0   0
  EVT                       339                   5                            2                       2                    346                   0                     1     1     341   7     346   2     345   1     2   
  Surgical reconstruction   433                   0                            2                       6                    437                   2                     0     2     435   6     403   38    438   2     1   
  Total                     776                   5                            4                       8                    787                   2                     1     3     780   13    753   40    787   3     3   
  b\. ASO                                                                                                                                                                                                                   
                            Cardiac disease       Cerebrovascular disease      Pneumonia               Wound complication   Peripheral embolism                                                                             
  (−)                       Angina                Serious arrhysmia            Myocardial infarction   (−)                  TIA                   Cerebral infarction   (−)   (+)   (−)   (+)   (−)   (+)                   
  Functional loss (−)       Functional loss (+)   Minor (including blue toe)   Major                                                                                                                                        
  Local condition           Rutherford 4          148                          0                       0                    3                     151                   0     0     0     149   2     145   6     150   0   1
  Rutherford 5              497                   4                            4                       4                    503                   2                     1     3     501   8     479   30    504   3     2   
  Rutherford 6              110                   1                            0                       1                    112                   0                     0     0     109   3     111   1     112   0     0   
  Therapeutic measures      Non-reconstruction    4                            0                       0                    0                     4                     0     0     0     4     0     4     0     4     0   0
  EVT                       334                   5                            2                       2                    341                   0                     1     1     336   7     341   2     340   1     2   
  Surgical reconstruction   417                   0                            2                       6                    421                   2                     0     2     419   6     390   35    422   2     1   
  Total                     755                   5                            4                       8                    766                   2                     1     3     759   13    735   37    766   3     3   

TIA: transient ischemic attack, EVT: endovascular treatment

###### Table 5-3 Perioperative complications 2

  a\. Total                                                                                                                                                                                                                     
  ------------------------- -------------------- ------------------- --------------------- ------------------------------------- ------------------------------- ------- --------- ------ -------- ----- ----- ----- ----- ---- ---
  Local condition           Rutherford 4         155                 1                     0                                     0                               1       9         1      0        0     0     156   0     83   0
  Rutherford 5              514                  10                  0                     0                                     2                               2       10        1      0        0     522   2     292   1    
  Rutherford 6              111                  2                   0                     0                                     0                               0       2         0      0        0     113   0     48    1    
  Therapeutic measures      Non-reconstruction   4                   0                     0                                     0                               0       0         0      0        0     0     4     0     11   1
  EVT                       348                  0                   0                     0                                     0                               0       0         0      0        0     346   2     350   1    
  Surgical reconstruction   428                  13                  0                     0                                     3                               11      13        1      0        0     441   0     62    0    
  Total                     780                  13                  0                     0                                     3                               11      13        1      0        0     791   2     423   2    
  b\. ASO                                                                                                                                                                                                                       
                            Hemorrhage           Sites of bleeding   Outcome of bleeding   Complication due to contrast medium   Complication at puncture site                                                                  
  (−)                       (+)                  Unknown             Brain                 GI tract                              Others                          Cured   Uncured   Dead   Others   (−)   (+)   (−)   (+)        
  Local condition           Rutherford 4         150                 1                     0                                     0                               1       9         1      0        0     0     151   0     82   0
  Rutherford 5              499                  10                  0                     0                                     2                               2       10        1      0        0     507   2     287   1    
  Rutherford 6              110                  2                   0                     0                                     0                               0       2         0      0        0     112   0     48    1    
  Therapeutic measures      Non-reconstruction   4                   0                     0                                     0                               0       0         0      0        0     0     4     0     11   1
  EVT                       343                  0                   0                     0                                     0                               0       0         0      0        0     341   2     345   1    
  Surgical reconstruction   412                  13                  0                     0                                     3                               11      13        1      0        0     425   0     61    0    
  Total                     759                  13                  0                     0                                     3                               11      13        1      0        0     770   2     417   2    

GI: gastrointestinal, EVT: endovascular treatment

###### Table 5-4 Hemodynamics

  a\. Total                                                                                                                                                                        
  ------------------------- ------------------------------- ------------------------------- -------- ---------------- -------- ---- -------- ------ -------- ----- -------- ------ ------
  Local condition           Rutherford 4                    76                              0.83     73               114      41   30       73     0.90     72    115      18     41.5
  Rutherford 5              234                             0.87                            220      115.5            190      40   186      0.88   175      123   85       43     
  Rutherford 6              31                              0.98                            30       130              34       33   28       0.99   27       122   17       44     
  Therapeutic measures      Non-reconstruction              8                               0.675    6                97.5     7    19       12     0.90     12    118.5    8      27
  EVT                       173                             0.79                            161      112              133      36   133      0.86   123      116   70       41.5   
  Surgical reconstruction   160                             0.91                            156      120.5            125      41   142      0.92   139      121   46       45     
  Total                     341                             0.87                            323      117              265      38   287      0.89   274      119   120      43     
  b\. ASO                                                                                                                                                                          
                            Immediate after the treatment   One month after the treatment                                                                                          
  ABI                       Ankle pressure                  SPP                             ABI      Ankle pressure   SPP                                                          
  n                         Median                          n                               Median   n                Median   n    Median   n      Median   n     Median          
  Local condition           Rutherford 4                    73                              0.81     70               109      40   29       70     0.90     69    114      18     41.5
  Rutherford 5              230                             0.86                            216      115.5            188      40   184      0.88   173      123   84       43     
  Rutherford 6              31                              0.98                            30       130              33       33   28       0.99   27       122   17       44     
  Therapeutic measures      Non-reconstruction              8                               0.675    6                97.5     7    19       12     0.90     12    118.5    8      27
  EVT                       172                             0.79                            160      111.5            133      36   132      0.86   122      116   70       41.5   
  Surgical reconstruction   154                             0.905                           150      120.5            121      41   138      0.92   135      122   45       45     
  Total                     334                             0.865                           316      116.5            261      38   282      0.89   269      119   119      43     

ABI: ankle brachial (pressure) index, SPP: skin perfusion pressure, EVT: endovascular treatment

###### Table 5-5 Condition of the limbs

  a\. Total                                                                                                                                                                                                                                                                                                                    
  ------------------------- ----------------------------- ------------------------------- ---------------- ------------------------------------------------------------ ----------- -------- ---------- ----------- -------------- ------- --------- --------- ------------ ---------------------- --------------- ----- ----- ----
  Local condition           Rutherford 4                  142                             3                5                                                            0           0        2          0           137            19      2         105       38           8                      7               115   32    20
  Rutherford 5              477                           10                              27               0                                                            2           2        4          445         62             18      97        329       92           7                      295             123   134   
  Rutherford 6              91                            5                               8                0                                                            1           0        1          82          12             4       11        69        18           0                      31              38    49    
  Therapeutic measures      Non-reconstruction            0                               0                0                                                            0           0        0          0           16             2       3         8         9            2                      2               24    7     5
  EVT                       310                           12                              19               0                                                            0           0        3          256         58             15      79        183       62           5                      179             83    90    
  Surgical reconstruction   400                           6                               21               0                                                            3           4        2          392         33             6       126       244       54           7                      238             103   108   
  Total                     710                           18                              40               0                                                            3           4        5          664         93             24      213       436       118          14                     441             193   203   
  b\. ASO                                                                                                                                                                                                                                                                                                                      
                            Bypass graft/ EVT condition   Clinical symptoms of the limb   Ischemic wound   Ambulatory function at discharge (Taylor's classification)                                                                                                                                                          
  Good                      Stenosis                      Occlusion                       Deterioration    Anastomosis disruption (aneurysm)                            Infection   Others   Improved   No change   Deteriorated   Cured   Uncured   Unknown   Ambulatory   Ambulatory/homebound   Nonambulatory               
  Improved                  Deteriorated                                                                                                                                                                                                                                                                                       
  Local condition           Rutherford 4                  138                             3                5                                                            0           0        1          0           133            19      2         103       36           8                      7               111   31    20
  Rutherford 5              466                           10                              23               0                                                            2           2        4          435         62             15      95        322       88           7                      286             119   132   
  Rutherford 6              90                            5                               8                0                                                            1           0        1          81          12             4       11        68        18           0                      31              37    49    
  Therapeutic measures      Non-reconstruction            0                               0                0                                                            0           0        0          0           16             2       3         8         9            2                      2               24    7     5
  EVT                       306                           12                              18               0                                                            0           0        3          254         58             12      78        182       59           5                      176             82    89    
  Surgical reconstruction   388                           6                               18               0                                                            3           3        2          379         33             6       123       235       53           7                      228             98    107   
  Total                     694                           18                              36               0                                                            3           3        5          649         93             21      209       426       114          14                     428             187   201   

EVT: endovascular treatment

###### Table 5-6 Revision of treatment

  a\. Total                                                                                                                                                                                                                                                                                                                                                
  --------------------------- -------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------- ------------------ -------- ----- ------------------------------ -------------- ----- ----------- ------------- --------------- -------- ----- ----- ----- --- ---
  Local condition             Rutherford 4                                                   7                                              6                                               150                0        2     0                              146            1     0           0             5               0        0     0     157   4   1
  Rutherford 5                34                                                             14                                             498                                             2                  16       4     490                            6              0     2           12            7               1        2     517   18    3   
  Rutherford 6                14                                                             2                                              96                                              0                  4        1     89                             4              0     2           4             1               0        1     97    10    1   
  Therapeutic measures        Non-reconstruction                                             0                                              0                                               0                  0        0     0                              0              0     0           0             0               0        0     0     30    2   0
  EVT                         23                                                             14                                             325                                             1                  12       1     316                            0              0     3           13            4               1        2     322   18    1   
  Surgical reconstruction     32                                                             8                                              419                                             1                  10       4     409                            11             0     1           8             4               0        1     419   12    4   
  Total                       55                                                             22                                             744                                             2                  22       5     725                            11             0     4           21            8               1        3     771   32    5   
  b\. ASO                                                                                                                                                                                                                                                                                                                                                  
                              Revision for those excluding good bypass graft/EVT condition   Minor reintervention (revision for stenosis)   Major reintervention (revision for occlusion)   Major amputation                                                                                                                                               
  (+)                         (−)                                                            (−)                                            Patch plasty                                    EVT                Others   (−)   Thrombectomy (±patch plasty)   Thrombolysis   EVT   Re-bypass   Jump bypass   Interposition   Others   (−)   (+)             
  Due to preoperative wound   Due to new wound                                                                                                                                                                                                                                                                                                             
  Local condition             Rutherford 4                                                   6                                              6                                               145                0        2     0                              141            1     0           0             5               0        0     0     153   4   0
  Rutherford 5                31                                                             13                                             483                                             2                  16       4     477                            5              0     2           11            7               1        2     504   17    2   
  Rutherford 6                14                                                             2                                              95                                              0                  4        1     88                             4              0     2           4             1               0        1     96    10    1   
  Therapeutic measures        Non-reconstruction                                             0                                              0                                               0                  0        0     0                              0              0     0           0             0               0        0     0     30    2   0
  EVT                         22                                                             14                                             320                                             1                  12       1     312                            0              0     3           12            4               1        2     317   18    1   
  Surgical reconstruction     29                                                             7                                              403                                             1                  10       4     394                            10             0     1           8             4               0        1     406   11    2   
  Total                       51                                                             21                                             723                                             2                  22       5     706                            10             0     4           20            8               1        3     753   31    3   

EVT: endovascular treatment

###### Table 5-7 Condition of contralateral limbs

  a\. Total                                                                                                                                                                                                                                                                                                            
  ------------------------- -------------------------------------- ---------------------------------- ---------------- ------------------------- -------------------- ----- ----------------- ------------------ ------------------ ---------------------- ---------------------------- -------- ---- ---- --- --- --- ---
  Local condition           Rutherford 4                           59                                 48               11                        3                    4     1                 41                 5                  77                     0                            23       19   2    5   0   2   0
  Rutherford 5              165                                    172                                30               14                        47                   6     118               44                 239                1                      52                           61       8    23   0   7   2   
  Rutherford 6              26                                     44                                 3                3                         7                    3     32                14                 57                 0                      17                           11       2    7    0   0   1   
  Therapeutic measures      Non-reconstruction                     19                                 7                0                         2                    1     0                 7                  2                  12                     0                            4        2    1    1   0   0   0
  EVT                       106                                    119                                17               6                         24                   6     74                21                 171                1                      50                           18       2    18   0   4   1   
  Surgical reconstruction   125                                    138                                27               12                        33                   4     110               40                 190                0                      38                           71       9    16   0   5   2   
  Total                     250                                    264                                44               20                        58                   10    191               63                 373                1                      92                           91       12   35   0   9   3   
  b\. ASO                                                                                                                                                                                                                                                                                                              
                            Contralateral limb occlusive lesions   Treatment for contralateral limb                                                                                                                                                                                                                    
  (−)                       (+)                                    Unnecessary                        (+)                                                                                                                                                                                                              
  Asymptomatic              Intermittent claudication              CLI                                Post-treatment   Pharmacological therapy   Angiogenic therapy   EVT   Surgical bypass   Minor amputation   Major amputation   Lumber sympathectomy   Necessary but no treatment   Others                         
  R4                        R5                                     R6                                                                                                                                                                                                                                                  
  Local condition           Rutherford 4                           55                                 48               11                        2                    4     1                 41                 5                  76                     0                            23       19   2    5   0   2   0
  Rutherford 5              157                                    168                                30               13                        47                   6     116               43                 236                1                      51                           60       7    22   0   7   2   
  Rutherford 6              26                                     43                                 3                3                         7                    3     32                13                 57                 0                      17                           11       2    7    0   0   1   
  Therapeutic measures      Non-reconstruction                     19                                 7                0                         2                    1     0                 7                  2                  12                     0                            4        2    1    1   0   0   0
  EVT                       103                                    117                                17               6                         24                   6     74                21                 169                1                      50                           18       2    18   0   4   1   
  Surgical reconstruction   116                                    135                                27               10                        33                   4     108               38                 188                0                      37                           70       8    15   0   5   2   
  Total                     238                                    259                                44               18                        58                   10    189               61                 369                1                      91                           90       11   34   0   9   3   

CLI: critical limb ischemia, EVT: endovascular treatment

###### Table 5-8 Malignant neoplasm

  a\. Total                                                                                                                                                                                                                                      
  ------------------------- ------------------------------------ --------------------------------------------- --------------- ----------- ------ --------- ------------------------ ------- -------- -------- --------- ---------- -------- --- ---
  Local condition           Rutherford 4                         165                                           1               1           0      0         1                        0       0        0        0         0          0        0   0
  Rutherford 5              546                                  4                                             2               1           0      0         1                        0       0        1        0         0          0        1   
  Rutherford 6              118                                  0                                             0               0           0      0         0                        0       0        0        0         0          0        0   
  Therapeutic measures      Non-reconstruction                   33                                            0               3           0      0         0                        0       0        0        0         0          0        0   0
  EVT                       349                                  3                                             0               1           0      0         1                        0       0        1        0         0          0        0   
  Surgical reconstruction   447                                  2                                             0               0           0      1         0                        0       0        0        0         0          0        1   
  Total                     829                                  5                                             3               1           0      1         1                        0       0        1        0         0          0        1   
  b\. ASO                                                                                                                                                                                                                                        
                            Newly diagnosed malignant neoplasm   Sites of newly diagnosed malignant neoplasm                                                                                                                                     
  (−)                       (+)                                  Unknown                                       Head and neck   Esophagus   Lung   Stomach   Hepatobiliary pancreas   Colon   Breast   Uterus   Ovarium   Prostate   Others       
  Local condition           Rutherford 4                         160                                           1               1           0      0         1                        0       0        0        0         0          0        0   0
  Rutherford 5              531                                  4                                             2               1           0      0         1                        0       0        1        0         0          0        1   
  Rutherford 6              117                                  0                                             0               0           0      0         0                        0       0        0        0         0          0        0   
  Therapeutic measures      Non-reconstruction                   33                                            0               3           0      0         1                        0       0        0        0         0          0        0   0
  EVT                       344                                  3                                             0               1           0      0         1                        0       0        1        0         0          0        1   
  Surgical reconstruction   431                                  2                                             0               0           0      0         0                        0       0        0        0         0          0        0   
  Total                     808                                  5                                             3               1           0      1         1                        0       0        1        0         0          0        1   

EVT: endovascular treatment

4. Conclusions
==============

The devoted contribution of vascular surgeons in the participating facilities to register a sufficient amount of detailed data during busy clinical practice has been gradually clarifying the current status of CLI treatment in Japan; data on CLI in 2015 were clarified, after those in 2013 and 2014. The JCLIMB Committee is planning to continue publishing an annual report. Facilities can newly participate in JCLIMB at any time, and clinical studies utilizing these data will also be performed under specific conditions. Please contact the secretariat of the JSVS for details.

In the future, JCLIMB is designed so as to be extended to a system which physicians in departments other than vascular surgery will be able to register, track, and analyze CLI, aiming at establishing a nationwide CLI database in Japan.

5. Participant Facilities (92 facilities in the order of the Japanese syllabary by area, corporate names are omitted as a rule)
===============================================================================================================================

Department of Vascular Surgery, Asahikawa Medical University Hospital

Department of Cardiovascular Surgery, National Hospital Organization Obihiro Hospital

Department of Cardiovascular Surgery, National Hospital Organization Hokkaido Medical Center

Department of Cardiovascular Surgery, Steel Memorial Muroran Hospital

Department of Cardiovascular Surgery, Nayoro City General Hospital

Department of Surgery, Iwate Prefectural Iwai Hospital

Department of Surgery, Iwate Prefectural Isawa Hospital

Department of Cardiovascular Surgery, Iwate Prefectural Central Hospital

Department of Surgery, Iwate Prefectural Chubu Hospital

Department of Surgery, JR Sendai Hospital

Department of Surgery and Cardiovascular Surgery, Sendai City Hospital

Department of Transplantation, Reconstruction and Endoscopic Surgery, Tohoku University Hospital

Department of Cardiovascular Surgery, Southern TOHOKU General Hospital

Department of Thoracic and Cardiovascular Surgery, Hirosaki University Hospital

Department of Vascular Surgery, Morioka Yuai Hospital

Department of Cardiovascular Surgery, Akita Kouseiren Yurikumiai General Hospital

Department of Cardiovascular Surgery, Itabashi Chuo Medical Center

Department of Vascular Surgery, Ibaraki Prefectural Central Hospital

Department of Cardiovascular Surgery, IMS Tokyo Katsushika General Hospital

Department of Vascular Surgery, Edogawa Hospital

Department of Vascular Surgery, Kawasaki Municipal Hospital

Department of Cardiovascular Surgery, Kyorin University Hospital

Department of Surgery, Keio University Hospital

Department of Surgery, Tokyo Metropolitan Health and Medical Treatment Corporation, Okubo Hospital

Department of Vascular Surgery, International University of Health and Welfare Hospital

Department of Vascular Surgery, International University of Health and Welfare, Mita Hospital

Department of Vascular Surgery, Saiseikai Kawaguchi General Hospital

Department of Vascular Surgery, Saiseikai Yokohamashi Tobu Hospital

Department of Vascular Surgery, Saitama Medical Center

Department of Surgery, Saitama City Hospital

Department of Cardiovascular Surgery, Saitama Medical Center, Jichi Medical University

Department of Surgery, Shonankamakura General Hospital

Department of Cardiovascular Surgery, St. Marianna University School of Medicine

Department of Cardiovascular Surgery, Shimada General Hospital

Department of Cardiovascular Surgery, Chiba Central Medical Center

Department of Vascular Surgery, Tokyo Medical and Dental University

Department of Cardiovascular Surgery, Tokyo Medical University Hachioji Medical Center

Department of Cardiovascular Surgery, Tokyo Medical University Hospital

Department of Vascular Surgery, The Jikei University Kashiwa Hospital

Department of Vascular Surgery, The Jikei University Hospital

Department of Cardiovascular Surgery, Tokyo Women's Medical University Medical Center East

Department of Vascular Surgery, The University of Tokyo Hospital

Department of Cardiovascular Surgery, Tokyo Rinkai Hospital

Department of Vascular Surgery, Tomei Atsugi Hospital

Department of Cardiovascular Surgery, Tokorozawa Meisei Hospital

Department of Cardiac and Vascular Surgery, Dokkyo Medical University Nikko Medical Center

Department of Cardiac and Vascular Surgery, Dokkyo Medical University Hospital

Department of Cardiovascular Surgery, National Defense Medical College Hospital

Department of Cardiovascular Surgery, Yokosuka General Hospital UWAMACHI

Department of Vascular Surgery, Aichi Medical University Hospital

Department of Vascular Surgery, Ichinomiya Municipal Hospital

Department of Cardiovascular Surgery, National Hospital Organization, Kanazawa Medical Center

Department of Vascular Surgery, Japanese Red Cross Shizuoka Hospital

Department of Vascular Surgery, Japanese Red Cross Nagoya Daiichi Hospital

Department of Vascular Surgery, Nagoya University Hospital

Department of Cardiovascular Surgery (Vascular Surgery), Osaka International Cancer Institute

Department of Vascular Surgery, Osaka Rosai Hospital

Department of Cardiovascular Surgery, Tsukazaki Hospital

Department of Vascular Surgery, Kansai Medical University Medical Center

Department of Cardiovascular Surgery, Kobe University Hospital

Department of Cardiovascular Surgery, Toyonaka Municipal Hospital

Department of Surgery, Shinsuma General Hospital

Department of Vascular Surgery, Soryukai Inoue Hospital

Department of Cardiovascular Surgery, Hashimoto Municipal Hospital

Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University Hospital

Department of Cardiovascular Surgery, Ehime Prefectural Central Hospital

Department of Cardiovascular Surgery, Okayama University Hospital

Department of Cardiovascular Surgery, Kawasaki Medical School Hospital

Department of Cardiovascular Surgery, Kochi Health Sciences Center

Department of Cardiovascular Surgery, Kochi University Hospital

Department of Cardiovascular Surgery, National Hospital Organization Higashihiroshima Medical Center

Department of Vascular Surgery, Saiseikai Yamaguchi General Hospital

Department of Cardiovascular Surgery, Tottori Prefectural Central Hospital

Department of Cardiovascular Surgery, The Sakakibara Heart Institute of Okayama

Department of Cardiovascular and Respiratory Surgery, Hiroshima Prefectural Hospital

Department of Surgery, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Department of Cardiovascular Surgery, Hiroshima University Hospital

Department of Cardiovascular Surgery, Matsuyama Shimin Hospital

Department of Vascular Surgery, Matsuyama Red Cross Hospital

Department of Vascular Surgery, Yamaguchi University Hospital

Department of Cardiovascular Surgery, Oita Oka Hospital

Department of Vascular Surgery, Kyushu University Hospital

Department of Vascular Surgery, Kumamoto Rehabilitation Hospital.

Cardiovascular Surgery, Kurume University Hospital

Department of Vascular Surgery, Kokura Memorial Hospital

Department of Vascular Surgery, National Hospital Organization Kyushu Medical Center

Department of Surgery, Saiseikai Karatsu Hospital

Department of Surgery, Saiseikai Fukuoka General Hospital

Department of Cardiovascular Surgery, Saga-ken Medical Center, Koseikan

Department of Cardiovascular Surgery, Sasebo Chuo Hospital

Department of Vascular Surgery, Steel Memorial Yawata Hospital

Department of Vascular Surgery, Fukuoka City Hospital
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(1) JCLIMB Steering Committee
-----------------------------
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------------------------------

Arata Takahashi and Hiroaki Miyata
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